Literature DB >> 28492015

A dermatologist guide to immunogenicity.

Collin M Blattner1, Soham P Chaudhari2, John Young3, Jenny E Murase4,5.   

Abstract

Dermatologists should be aware that autoantibody formation may occur after the initiation of biologic therapy. This phenomenon has been referred to as immunogenicity and biologic fatigue. Because of this, patients may experience loss of clinical efficacy to a particular drug. To combat this phenomenon, low-dose immunomodulators may be used in hopes of preventing autoantibodies. We review the current literature and provide a basic treatment algorithm for patients with moderate to severe psoriasis.

Entities:  

Keywords:  HACA antibodies; antidrug antibodies; autoantibodies; biologic fatigue; resistance to biologics

Year:  2016        PMID： 28492015      PMCID： PMC5418886          DOI： 10.1016/j.ijwd.2016.05.001

Source DB:  PubMed          Journal:  Int J Womens Dermatol        ISSN： 2352-6475


  45 in total

1.  Sequential treatment with biologics: switching from efalizumab to etanercept in 35 patients with high-need psoriasis.

Authors:  C Antoniou; C Dessinioti; T Vergou; A J Stratigos; G Avgerinou; M Kostaki; A Katsambas
Journal:  J Eur Acad Dermatol Venereol       Date:  2010-12       Impact factor: 6.166

2.  Combination therapy with ciclosporin and etanercept in patients with psoriatic arthritis.

Authors:  Salvatore D'Angelo; Maria Stefania Cutro; Ennio Lubrano; Pietro Leccese; Gianna Angela Mennillo; Nicola Ferrara; Ignazio Olivieri
Journal:  Ann Rheum Dis       Date:  2009-08-09       Impact factor: 19.103

Review 3.  Can we prevent immunogenicity of human protein drugs?

Authors:  D W Scott; A S De Groot
Journal:  Ann Rheum Dis       Date:  2010-01       Impact factor: 19.103

4.  Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis.

Authors:  Geertje M Bartelds; Carla A Wijbrandts; Michael T Nurmohamed; Steven Stapel; Willem F Lems; Lucien Aarden; Ben A C Dijkmans; Paul Peter Tak; Gerrit Jan Wolbink
Journal:  Ann Rheum Dis       Date:  2007-02-14       Impact factor: 19.103

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 6.  Review article: Infliximab therapy for inflammatory bowel disease--seven years on.

Authors:  P Rutgeerts; G Van Assche; S Vermeire
Journal:  Aliment Pharmacol Ther       Date:  2006-02-15       Impact factor: 8.171

7.  A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

Authors:  Alan Menter; Steven R Feldman; Gerald D Weinstein; Kim Papp; Robert Evans; Cynthia Guzzo; Shu Li; Lisa T Dooley; Cynthia Arnold; Alice B Gottlieb
Journal:  J Am Acad Dermatol       Date:  2006-09-06       Impact factor: 11.527

8.  Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris.

Authors:  Alexander Nast; Ina B Kopp; Matthias Augustin; Kirstin-Benita Banditt; Wolf-Henning Boehncke; Markus Follmann; Markus Friedrich; Matthias Huber; Christina Kahl; Joachim Klaus; Joachim Koza; Inga Kreiselmaier; Johannes Mohr; Ulrich Mrowietz; Hans-Michael Ockenfels; Hans-Dieter Orzechowski; Jörg Prinz; Kristian Reich; Thomas Rosenbach; Stefanie Rosumeck; Martin Schlaeger; Gerhard Schmid-Ott; Michael Sebastian; Volker Streit; Tobias Weberschock; Berthold Rzany
Journal:  J Dtsch Dermatol Ges       Date:  2007-07       Impact factor: 5.584

9.  A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.

Authors:  A B Gottlieb; R G Langley; B E Strober; K A Papp; P Klekotka; K Creamer; E H Z Thompson; M Hooper; G Kricorian
Journal:  Br J Dermatol       Date:  2012-09       Impact factor: 9.302

10.  Infliximab in the treatment of plaque type psoriasis.

Authors:  Rosita Saraceno; Andrea Saggini; Lucia Pietroleonardo; Sergio Chimenti
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-04-03
View more
  1 in total

1.  Immunogenicity to biological drugs in psoriasis and psoriatic arthritis.

Authors:  Fernando Valenzuela; Rodrigo Flores
Journal:  Clinics (Sao Paulo)       Date:  2021-10-01       Impact factor: 2.365
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.